Item 7.01 Regulation FD Disclosure.

On September 20, 2021, Syros Pharmaceuticals, Inc. (the "Company") held a conference call and webcast in which the Company's management reviewed a slide presentation describing, among other things, new data presented at the European Society for Medical Oncology Congress ("ESMO 2021") from the dose-escalation portion of the Company's Phase 1 clinical trial of SY-5609. This slide presentation is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

The information responsive to Item 7.01 of this Form 8-K and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On September 20, 2021, the Company issued a press release announcing new data presented at ESMO 2021 from the dose-escalation portion of the Company's Phase 1 clinical trial of SY-5609. The press release issued in connection with this announcement is attached as Exhibit 99.2 to this Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






Exhibit No.                                  Description

99.1                Slide Presentation, dated September 20, 2021

99.2                Press Release, dated September 20, 2021

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses